ClinicalTrials.gg
CompletedNCT07054970Updated Jul 8, 2025

To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects

A Phase 1 interventional study of CT-P55 and US-licensed Cosentyx in Healthy Male Subjects, sponsored by Celltrion. Completed at 4 sites in Japan. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Celltrion · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2024, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1, Randomized, Double-blind, three-arm, Parallel group, Single-dose Study to Compare the Pharmacokinetics, Safety and immunogenicity of CT-P55, EU-approved Cosentyx and US-licensed Cosentyx in Healthy male Subjects

Read the detailed description

CT-P55, containing the active ingredient secukinumab, is being developed by CELLTRION, Inc. as a proposed biosimilar to the reference product, Cosentyx. In this study, Pharmacokinetics, Safety and Immunogenicity of CT-P55, EU-approved Cosentyx and US-licensed Cosentyx were evaluated in Healthy Male Subjects.

02

Conditions studied

  • Healthy Male Subjects
03

In context

Lead sponsor

Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between the ages of 18 and 55 years, both inclusive.
  • Body weight between 50.0 kg and 90.0 kg (both inclusive), and (BMI) between 18.5 and 29.9 kg/m2 (both inclusive), when rounded to the nearest tenth.

Exclusion criteria

Exclusion Criteria:

  • A medical history and/or condition that is considered significant
  • allergic reactions,
  • History or current infection of , virus, virus or syphilis
  • Active or latent Tuberculosis
  • History of
  • Previous monoclonal antibody or fusion protein treatment, or current use of any biologics
  • Planning to be father a child or donate sperm within 22 weeks period following study drug administration.
  • Undergone treatment with an drug or participated in another clinical trial within 12weeks or 5 half-lives (whichever is longer)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    CT-P55

    a single subcutaneous (SC) injection via pre-filled syringe (PFS)

    Biological: CT-P55

  • Active comparator
    US-licensed Cosentyx

    a single SC injection via PFS

    Biological: US-licensed Cosentyx

  • Active comparator
    EU-approved Cosentyx

    a single SC injection via PFS

    Biological: EU-approved Cosentyx

Interventions

  • BiologicalCT-P55

    150 mg in 1.0 mL, administered as a single SC injection via PFS

  • BiologicalUS-licensed Cosentyx

    150 mg in 1.0 mL, administered as a single SC injection via PFS

  • BiologicalEU-approved Cosentyx

    150 mg in 1.0 mL, administered as a single SC injection via PFS

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) similarity demonstration in terms of area under the concentration-time curve (AUC) from time zero to infinity (AUC0-inf)

    Demonstrate PK similarity in terms of area under the concentration-time curve (AUC) from time zero to infinity (AUC0-inf) of CT-P55, European Union (EU)-approved Cosentyx and United States (US)-licensed Cosentyx in healthy male subjects. The similarity of PK will be concluded if the 90% Cls for the ratios of geometric means of the comparison are entirely contained within the equivalence margin of 80% to 125% for AUC0-inf.

    Time frame: Day 155

  2. PK similarity demonstration in terms of maximum serum concentration (Cmax)

    Demonstrate PK similarity in terms of Cmax of CT-P55, EU-approved Cosentyx and US-licensed Cosentyx in healthy male subjects up to Day 155. The similarity of PK will be concluded if the 90% Cls for the ratios of geometric means of the comparison are entirely contained within the equivalence margin of 80% to 125% for Cmax.

    Time frame: Day 155

Secondary outcomes

  1. Evaluate additional PK in terms of AUC from time zero to the last quantifiable concentration (AUC0-last)

    Time frame: Day 155

  2. Evaluate additional PK in terms of Time to Cmax (Tmax)

    Time frame: Day155

  3. Evaluate additional PK in terms of Apparent volume of distribution during the terminal phase after non-intravenous administration (Vz/F)

    Time frame: Day 155

  4. Evaluate additional PK in terms of Terminal elimination rate constant (λz)

    Time frame: Day155

  5. Evaluate additional PK in terms of Terminal elimination half-life (t1/2)

    Time frame: Day 155

  6. Evaluate additional PK in terms of Apparent total body clearance (CL/F)

    Time frame: Day155

  7. Evaluate additional PK in terms of Percentage of the area extrapolated for calculation of AUC0-inf (%AUCextrap)

    Time frame: Day 155

  8. Evaluate safety in terms of treatment-emergent adverse events (TEAEs) of CT-P55 as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: Day 155

07

Study locations

4 sites
  • Yokohama Minoru Clinic
    Yokohama, Kanagawa 232-0064, Japan
  • SOUSEIKAI Nishikumamoto Hospital
    Kumamoto, Kumamoto, Japan
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka, Osaka 532-0003, Japan
  • Kitasato University Kitasato Institute Hospital
    Minato-ku, Tokyo 108-8642, Japan
08

References and documents

Publications

  • Hasunuma T, Yagi M, Nakamichi N, Blauvelt A, Thaci D, Suh J, Cha J, Noh I, Lee E, Papp KA. Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study. Expert Opin Investig Drugs. 2026 Jan-Feb;35(2):179-188. doi: 10.1080/13543784.2026.2628208. Epub 2026 Feb 22. PubMed 41665131 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Aug 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2025
First posted
Jul 8, 2025
StartActual
Jan 12, 2024
Primary completionActual
Aug 29, 2024
CompletionActual
Sep 6, 2024
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07054970
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Jan 12, 2024
Primary completion
Aug 29, 2024
Completion
Sep 6, 2024
Last update
Jul 8, 2025

Study contacts

Tomoko Hasunuma
principal investigator · Kitasato University Kitasato Institute Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion